Words of Wisdom:

"''When all have failed, you should read the instructions''" - Ommondoitfloin

Spinal Muscular Atrophy Market to Be Driven by Increasing Number of Drug Candidates in Pipeline

  • Date Submitted: 07/15/2016 05:18 AM
  • Flesch-Kincaid Score: 35.9 
  • Words: 760
  • Essay Grade: no grades
  • Report this Essay
A new report, titled “Spinal Muscular Atrophy Market - Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023” has been published by Transparency Market Research. The study offers a detailed analysis of the spinal muscular atrophy market, providing insights into the pipeline assessment, major growth drivers, restraints, and potential opportunities. According to the research study, the spinal muscular atrophy phase three candidate ISIS-SMNRx is projected to generate revenue of US$0.47 by the end of 2023 in the U.S.

Browse the Full Report at :
http://www.transparencymarketresearch.com/spinal-muscular-atrophy-market.html

Spinal muscular atrophy (SMA) is one of the rare neuromuscular disorder that affects certain parts of the nervous system, which controls the muscle movement. In the last few years, there has been an increase in the number of SMA cases across the globe. Spinal muscular atrophy is considered as one of the prominent genetic disorders resulting in mortality among infants. The spinal muscular atrophy market has been classified on the basis of symptoms into type 1, type 2, type 3, and type 4 spinal muscular atrophy. Type 1 SMA is referred as the most severe form that affects infants aged 1 to 6 months. As per the report, around 60% of the overall SMA cases are of type 1, in which infants do not live more than two years. Type 2 SMA is considered moderate, which affects children between 6 and 18 months. Type 3 and type 4 patients mostly have a normal life expectancy.

The research study further discusses the pipeline of the spinal muscular atrophy. Early stage candidates and late stage candidates are the two major segments studied in the report. At present, ISIS-SMNRx by Ionis Pharmaceuticals, Inc. is the only late stage drug candidate present in the spinal muscular atrophy pipeline. Furthermore, three drugs are in phase 2 and three others are in phase 1 in the SMA pipeline. The rising research activities are expected to introduce more...

Comments

Express your owns thoughts and ideas on this essay by writing a grade and/or critique.

  1. No comments